REG - BSF Enterprise PLC - Admission to Trading and First Day of Dealings

BSF EnterpriseAnnouncement

17/05/2022 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220517:nRSQ6769La&default-theme=true

RNS Number : 6769L  BSF Enterprise PLC  17 May 2022

17 May 2022

BSF Enterprise PLC

("BSF" or "the Company")

Admission to Trading and First Day of Dealings

Following the successful reverse takeover of 3D Bio-Tissues Limited ("3DBT"),
a tissue engineering business based in Newcastle, UK, the Company announces
admission of the enlarged group to the standard segment of the Official List
and initiation of trading on the London Stock Exchange's Main Market at 8.00
a.m. today under the ticker 'BSFA' ("Admission"). The Admission follows a
placing which raised £1.75m at a placing price of 7.37 pence per share.

About 3DBT

●     A tissue engineering company with patent-protected IP that is
already producing human corneas that could help restore vision to millions of
people

●     It has three strands of IP, each with a different sector focus,
development and revenue timeline:

●     Serum-free media: 3DBT's City-mix™ is an animal-free cell growth
agent for culturing skin, muscle & fat cells which will be used for
lab-grown meat and leather production

●     Skin Care Products: Lipopeptide Etsyl™ actively increases
collagen production in human skin cells which can be used in cosmetic and skin
care products

●     Tissue Templating Application: using a platform to grow different
tissues with natural structure & function such as corneas, lab-grown meat
and leather & human skin substitutes

●     Building on its success to date, 3DBT is focused on producing the
UK's first 100% lab-grown meat in the next 12 months

●     The funds raised will be used to expand the team and to market the
Company's animal-free cell growth agent (serum free media) and cosmetics

●     Strong management team with over 20 years' experience in
extracellular matrix biology and tissue engineering - globally recognised
experts in molecular biology

About BSF

●     Aim to accelerate the tissue engineering sector, which includes
the growth of cell-laden structures including production of high quality,
lab-grown meat and leather

●     Experienced Board with a clear strategy - acquire, develop and
license technology in cultured animal tissue and related products

●     Operating in fast growing and transformative markets - 410% CAGR
(2021 to 2030) for lab-grown meat; 12.7m people currently awaiting cornea
transplant.

Geoff Baker, Executive Director of BSF, commented:

"Our successful acquisition of 3DBT provides investors with exposure to an
extremely exciting suite of IP which can be used for multiple applications
across numerous fast-growing and transformative markets, including the lab
grown meat and leather markets, as well as skin care.

"The skilled 3DBT team has already produced the world's first human corneas,
which is a fantastic feat given that 12.7m people worldwide are currently
awaiting a cornea transplant.

"Together, we are now focused on building on this success, creating value by
executing on the different verticals that our technology can be applied to.
The market for lab-grown meat - which is expected to grow at a CAGR of 410% to
2030 - is just one of these, and our aim to produce the UK's first cut of
cultured meat in the next 12 months is expected to open doors to potential
customers in the food supply chain. Importantly, demand for high-quality
alternative protein sources is high, driven by the critical need to reduce
global greenhouse gases, for which livestock farming is responsible for a
staggering 24%.

"Our technology has the potential to improve the lives of millions of people
around the world, and we would like to take this opportunity to thank our
investors for their support in delivering this exciting milestone."

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                             0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882

 Elisabeth Cowell                        BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFLREDIRLIF